Table 2

SACT regimen received in 1L and 2L of therapy, overall and by time period in patients with incident stage IIIB–IV NSCLC at diagnosis

Overall2007–20122013–2017
N (%)n (%)n (%)
1L of therapy648338310
 Platinum-based chemotherapy**549 (84.7)292 (86.4)257 (82.9)
  Carboplatin based456 (70.4)258 (76.3)198 (63.9)
  Cisplatin based93 (14.3)34 (10.1)59 (19.0)
 Pemetrexed containing treatments225 (34.7)86 (27.0)139 (44.8)
 Non-platinum chemotherapy7 (1.1)7 (2.1)0
 TKIs63 (9.7)21 (6.2)42 (13.5)
  Gefitinib29 (4.5)15 (4.4)14 (4.5)
  Erlotinib15 (2.3)3 (0.9)12 (3.9)
  Afatinib13 (2.0)013 (4.2)
 Checkpoint inhibitors (anti-PD-L1)7 (1.1)07 (2.3)
  Pembrolizumab7 (1.1)07 (2.3)
 Clinical trial22 (3.4)<20<5
2L of therapy223119104
 Platinum-based chemotherapy34 (15.2)11 (9.2)23 (22.1)
 Non-platinum chemotherapy21 (9.4)8 (6.7)13 (12.5)
  Docetaxel16 (7.2)5 (4.2)11 (10.6)
 TKIs141 (63.2)99 (83.2)42 (40.4)
  Erlotinib113 (50.7)96 (80.7)17 (16.3)
  Crizotinib7 (3.1)07 (6.7)
  Nintedanib + docetaxel10 (4.5)010 (9.6)
 Checkpoint inhibitors (anti-PD-L1)19 (8.5)019 (18.3)
  Pembrolizumab10 (4.5)010 (9.6)
  Nivolumab7 (3.1)07 (6.7)
 Clinical trial6 (2.7)06 (5.8)
  • Patient numbers <5 have been masked; data are not shown for treatments with patient numbers <5 for all populations shown.

  • *Platinum based chemotherapy included any regimen with a platinum agent as monotherapy or in combination, and was further defined as ‘carboplatin based’, ‘cisplatin based’ (including regimens where carboplatin and cisplatin were both used) and ‘pemetrexed included’ (any platinum-based regimen also including pemetrexed).

  • 1L, first-line therapy; 2L, second-line therapy; NSCLC, non-small cell lung cancer; PD-L1, programmed death ligand 1; SACT, systematic anticancer therapy; TKIs, tyrosine kinase inhibitors.